Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QR0E | ISIN: US2075231017 | Ticker-Symbol:
NASDAQ
25.06.25 | 22:00
0,960 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CONNECT BIOPHARMA HOLDINGS LTD ADR Chart 1 Jahr
5-Tage-Chart
CONNECT BIOPHARMA HOLDINGS LTD ADR 5-Tage-Chart

Aktuelle News zur CONNECT BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.06.Connect Biopharma reports positive data for asthma treatment2
13.06.Connect Biopharma meldet positive Daten für Asthma-Behandlung3
CONNECT BIOPHARMA Aktie jetzt für 0€ handeln
13.06.Connect Biopharma Holdings Limited: Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress3
10.06.Connect Biopharma files $300M mixed securities shelf2
10.06.Connect Biopharma Holdings Ltd - S-8, Securities to be offered to employees in employee benefit plans1
03.06.Connect Biopharma Holdings Limited: Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress1
20.05.Connect Biopharma Announces Significant Findings Regarding Rademikibart303BEIJING (dpa-AFX) - Connect Biopharma Holdings Limited (CNTB), Tuesday announced clinical and preclinical data regarding rademikibart for the treatment of patients with asthma or COPD experiencing...
► Artikel lesen
15.05.Connect Biopharma Posts Wider Loss In Q1254BEIJING (dpa-AFX) - Connect Biopharma Holdings (CNTB) posted a net loss of $10.3 million, or $0.19 per share, for the three months ended March 31, 2025, compared with a net loss of $8.7 million...
► Artikel lesen
15.05.Connect Biopharma GAAP EPS of -$0.19 beats by $0.073
15.05.Connect Biopharma Holdings Ltd - 10-Q, Quarterly Report3
14.05.Connect Biopharma Holdings Limited: Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD296- Expect to report topline data from the Seabreeze STAT COPD study in 1H 2026 - SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect...
► Artikel lesen
13.05.Connect Biopharma begins Phase 2 asthma study2
13.05.Connect Biopharma Holdings Ltd - 8-K, Current Report2
13.05.Connect Biopharma Holdings Limited: Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma230- Expect to report topline data from the Seabreeze STAT Asthma study in 1H 2026 - - On track to initiate similarly-designed Phase 2 study in patients with COPD imminently - SAN DIEGO, May 13, 2025...
► Artikel lesen
11.04.RedChip Companies, Inc.: Bullfrog AI and Connect Biopharma Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV284ORLANDO, FLORIDA / ACCESS Newswire / April 11, 2025 / RedChip Companies will air interviews with Bullfrog AI Holdings, Inc. (Nasdaq:BFRG) and Connect Biopharma Holdings Limited (Nasdaq:CNTB) and on...
► Artikel lesen
01.04.Connect Biopharma Reports Positive Type C Meeting With The FDA For Rademikibart312BEIJING (dpa-AFX) - Clinical-stage biopharmaceutical company Connect Biopharma Holdings Ltd. (CNTB) Tuesday announced positive feedback from its Type C meeting with the U.S. Food and Drug Administration...
► Artikel lesen
01.04.FDA greenlights Connect Biopharma's asthma and COPD trials4
01.04.Connect Biopharma Holdings Limited: Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart143- FDA aligned on plan to initiate parallel Phase 2 trials of rademikibart in patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation - - Expect to initiate both trials in...
► Artikel lesen
01.04.Connect Biopharma stock holds $8 target, Buy rating at H.C. Wainwright2
31.03.Connect Biopharma Holdings Limited: Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update274Strengthened leadership team with key appointments, including Barry Quart, Pharm.D. as CEO, and David Szekeres as President, bringing deep clinical, regulatory, operational and strategic expertise...
► Artikel lesen
Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1